Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and sells a broad portfolio of products spanning diagnostics, medical devices, nutrition and branded generic pharmaceuticals. Its diagnostic segment includes instruments and reagents for point‑of‑care testing, laboratory assays and molecular diagnostics, while its medical devices business offers cardiovascular, diabetes care and neuromodulation products such as glucose monitoring systems, implantable cardiac devices and vascular stents. The nutrition division supplies infant formula, adult nutritional supplements and specialty products under brands like Similac, Pedialyte and Ensure, and the pharmaceuticals unit provides generic drugs in areas such as central nervous system, women’s health and gastroenterology. Abbott serves hospitals, clinics, retail pharmacies and consumers in more than 160 countries, addressing needs across both developed and emerging markets.

Headquartered in Abbott Park, Illinois, United States of America, the company operates as a publicly traded corporation listed on the New York Stock Exchange under the ticker ABT. Abbott employs roughly 115,000 people worldwide and reports annual revenues in excess of $40 billion, reflecting its extensive manufacturing footprint and research‑and‑development network that includes facilities in the United States, Europe, Asia and Latin America. A distinguishing attribute of the company is its long history of innovation, dating back to its founding in 1888, which has yielded numerous first‑to‑market technologies such as the first portable blood glucose monitor and early rapid COVID‑19 antigen tests. Abbott’s integrated business model allows it to leverage cross‑segment synergies, for example using diagnostic insights to inform device development and nutritional science to support pharmaceutical formulations. The firm maintains a strong regulatory compliance posture, working closely with agencies such as the U.S. Food and Drug Administration and the European Medicines Agency to meet stringent safety and efficacy standards. Ownership remains dispersed among institutional and individual shareholders, with no single parent entity controlling the organization.